Epidermal Growth Factor Receptor Tyrosine Kinase Defines Critical Prognostic Genes of Stage I Lung Adenocarcinoma
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
PURPOSE: To identify stage I lung adenocarcinoma patients with a poor prognosis who will benefit from adjuvant therapy. PATIENTS AND METHODS: Whole gene expression profiles were obtained at 19 time points over a 48-hour time course from human primary lung epithelial cells that were stimulated with epidermal growth factor (EGF) in the presence or absence of a clinically used EGF receptor tyrosine kinase (RTK)-specific inhibitor, gefitinib. The data were subjected to a mathematical simulation using the State Space Model (SSM). "Gefitinib-sensitive" genes, the expressional dynamics of which were altered by addition of gefitinib, were identified. A risk scoring model was constructed to classify high- or low-risk patients based on expression signatures of 139 gefitinib-sensitive genes in lung cancer using a training data set of 253 lung adenocarcinomas of North American cohort. The predictive ability of the risk scoring model was examined in independent cohorts of surgical specimens of lung cancer. RESULTS: The risk scoring model enabled the identification of high-risk stage IA and IB cases in another North American cohort for overall survival (OS) with a hazard ratio (HR) of 7.16 (P = 0.029) and 3.26 (P = 0.0072), respectively. It also enabled the identification of high-risk stage I cases without bronchioalveolar carcinoma (BAC) histology in a Japanese cohort for OS and recurrence-free survival (RFS) with HRs of 8.79 (P = 0.001) and 3.72 (P = 0.0049), respectively. CONCLUSION: The set of 139 gefitinib-sensitive genes includes many genes known to be involved in biological aspects of cancer phenotypes, but not known to be involved in EGF signaling. The present result strongly re-emphasizes that EGF signaling status in cancer cells underlies an aggressive phenotype of cancer cells, which is useful for the selection of early-stage lung adenocarcinoma patients with a poor prognosis. TRIAL REGISTRATION: The Gene Expression Omnibus (GEO) GSE31210.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032 · cited 1×
“The final risk scoring model was also validated using the publicly available Duke cohort [20].”
MethodDirector's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma (2008) · Nature Medicine · doi:10.1038/nm.1790 · Cited by 1,190 · cited 5×
“Risk scoring model based on gefitinib-sensitive genes as predictors of the prognosis of lung adenocarcinoma cases The gene expression profiles of a total of 439 lung adenocarcinoma tissues derived from the NCI consortium project were used [18].”
MethodA Five-Gene Signature and Clinical Outcome in Non–Small-Cell Lung Cancer
Chen, H.-Y., Yu, S.-L., Chen, C.-H., Chang, G.-C., Chen, C.-Y., Yuan, A., Cheng, C.-L., Wang, C.-H., Terng, H.-J., Kao, S.-F., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060096 · Cited by 935 · cited 2×
“Several whole gene expression profiling studies have been conducted to obtain gene signatures applicable as biomarkers for clinical use [4,5,6,7,8,9,10,11].”
BackgroundOkayama, H., Kohno, T., Ishii, Y., Shimada, Y., Shiraishi, K., Iwakawa, R., Furuta, K., Tsuta, K., Shibata, T., Yamamoto, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1403 · Cited by 874
Self-citationRoles for Growth Factors in Cancer Progression
Witsch, E., Sela, M., & Yarden, Y. (2010) · Physiology · doi:10.1152/physiol.00045.2009 · Cited by 526 · cited 1×
“Epidermal growth factor (EGF) signaling affects a variety of cellular processes linked to aggressive phenotypes of lung and other cancer cells, such as growth, invasion, and metastasis [12,13].”
BackgroundSmart drugs: Tyrosine kinase inhibitors in cancer therapy
Shawver, L. K., Slamon, D., & Ullrich, A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00039-9 · Cited by 522 · cited 1×
“When cells were stimulated with EGF in the presence of an EGFR tyrosine kinase-specific inhibitor, gefitinib [16], the expression patterns of genes that were unpredictable due to inhibition of EGFR tyrosine kinase were designated as gefitinib-sensitive genes.”
BackgroundA module of negative feedback regulators defines growth factor signaling
Amit, I., Citri, A., Shay, T., Lu, Y., Katz, M., Zhang, F., Tarcic, G., Siwak, D., Lahad, J., Jacob-Hirsch, J., et al. (2007) · Nature Genetics · doi:10.1038/ng1987 · Cited by 488 · cited 2×
“5-fold differences in expression levels between EGF-treated and untreated cells at any time point from 0 to 9 hours, when a subset of the EGF response genes can be detected by this method [17] (Figure S1).”
BackgroundMethodZhu, C.-Q., Ding, K., Strumpf, D., Weir, B. A., Meyerson, M., Pennell, N., Thomas, R. K., Naoki, K., Ladd-Acosta, C., Liu, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.4325 · Cited by 471
Cited by
Győrffy, B., Surowiak, P., Budczies, J., & Lánczky, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082241 · Cited by 1,760
Sun, M., Nie, F., Wang, Y., Zhang, Z., Hou, J., He, D., Xie, M., Xu, L., De, W., Wang, Z., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0356 · Cited by 469
Aissa, A. F., Islam, A. B. M. M. K., Ariss, M. M., Go, C. C., Rader, A. E., Conrardy, R. D., Gajda, A. M., Rubio-Perez, C., Valyi-Nagy, K., Pasquinelli, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21884-z · Cited by 273
Zuo, S., Wei, M., Wang, S., Dong, J., & Wei, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01218 · Cited by 224
“Microarray and clinical data of LUAD patients were obtained from the GSE31210 (n = 226) (17, 18), GSE37745 (n = 106) (19, 20), and GSE50081 (n = 128) (21) datasets of the GEO database.”
MethodA pan-cancer analysis of the prognostic and immunological role of β-actin (ACTB) in human cancers
Gu, Y., Tang, S., Wang, Z., Cai, L., Lian, H., Shen, Y., & Zhou, Y. (2021) · Bioengineered · doi:10.1080/21655979.2021.1973220 · Cited by 99
Nigro, A., Ricciardi, L., Salvato, I., Sabbatino, F., Vitale, M., Crescenzi, M. A., Montico, B., Triggiani, M., Pepe, S., Stellato, C., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03135 · Cited by 70
Metadata
- Authors
- Yamauchi, M., Yamaguchi, R., Nakata, A., Kohno, T., Nagasaki, M., Shimamura, T., Imoto, S., Saito, A., Ueno, K., Hatanaka, Y., Yoshida, R., Higuchi, T., Nomura, M., Beer, D. G., Yokota, J., Miyano, S., & Gotoh, N.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-09-19
- Volume
- 7
- Issue
- 9
- Pages
- e43923
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1992367671
- Cited by
- 199
- References
- 22
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.